Alopexx, Inc. (ALPX)
| Market Cap | 38.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -956,954 |
| Shares Out | 7.68M |
| EPS (ttm) | -0.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About ALPX
Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow t... [Read more]
Financial Performance
Financial StatementsNews
Alopexx To Raise ~$15m IPO With Ambition To Drive Blockbuster Sales As Prevnar's Partner
Alopexx' IPO will take place on 12th October. The tiny biotech is working on two assets targeting the PNAG polysaccharide, which may impact the virulence of some bacteria.
IPO Update: Alopexx Readies $15 Million U.S. IPO
Alopexx has filed proposed terms to raise $15 million in a U.S. IPO. The company is developing drug candidates to treat infections.
Alopexx IPO Registration Document (S-1)
Alopexx has filed to go public with an IPO on the NASDAQ.
Biopharma financings cut by a third, transactions track with 2019 and earlier
Financings in the first two months of 2022 amount to only a third of the money raised during the same timeframe of 2021 and the number of transactions is down by 56 percent.
Infectious disease biotech Alopexx files for a $17 million IPO
Alopexx, a Phase 2 biotech developing immune therapies for bacterial, fungal, and parasitic infections, filed on Monday with the SEC to raise up to $17 million in an initial public offering.